NasdaqGS · Biotechnology

Madrigal Pharmaceuticals (MDGL)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+31.2%

$678.06 average target

$516.74-2.35 (-0.5%)Latest market snapshot · Yahoo Finance

Market cap$11.94B

Cash$838.8M

Quarterly burn$23.3M

Pipeline assets3

Short float10.0%

Clinical portfolio

Madrigal Pharmaceuticals Drug Pipeline

Showing 1 of 3

Asset	Indication	Stage	Milestone	Signals ?
Rezdiffra (Resmetirom) (MGL-3196)	Liver disease, Cirrhosis	Phase 3	Dec 31, 2027	—

Continue with BioPharma ProUnlock 2 additional programs and complete development details.

Unlock Pro

Upcoming milestones

MDGL Catalyst Timeline

1 currently tracked

Dec 31, 2027

Rezdiffra (Resmetirom) (MGL-3196)

Phase 3

Liver disease, Cirrhosis

Data readout

Event details

Company profile

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.